抗癌免疫毒素疗法的进展。
Advances in anticancer immunotoxin therapy.
作者信息
Alewine Christine, Hassan Raffit, Pastan Ira
机构信息
Laboratory of Molecular Biology and Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Laboratory of Molecular Biology and Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
出版信息
Oncologist. 2015 Feb;20(2):176-85. doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5.
Abstract
Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing. Immunotoxins kill cells by inhibiting protein synthesis, a unique mechanism of action that is toxic to both dividing and nondividing cells. Recent advances in the design and administration of immunotoxins are overcoming historical challenges in the field, leading to renewed interest in these therapeutics.
摘要
免疫毒素是一类新型的抗体偶联疗法，目前正处于针对多种恶性肿瘤的临床开发阶段。它们由一个基于抗体的靶向结构域与一个用于细胞杀伤的细菌毒素载荷融合而成。免疫毒素通过抑制蛋白质合成来杀死细胞，这是一种独特的作用机制，对分裂细胞和非分裂细胞均有毒性。免疫毒素设计和给药方面的最新进展正在克服该领域的历史挑战，引发了对这些疗法的新关注。
相似文献
1
Advances in anticancer immunotoxin therapy.
Oncologist. 2015 Feb;20(2):176-85. doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5.
2
Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
In Vivo. 2000 Jan-Feb;14(1):21-7.
3
Anti-cancer Immunotoxins, Challenges, and Approaches.
Curr Pharm Des. 2021;27(7):932-941. doi: 10.2174/1381612826666201006155346.
4
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001.
5
Immunotoxin therapy of cancer.
Nat Rev Cancer. 2006 Jul;6(7):559-65. doi: 10.1038/nrc1891.
6
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Cancer Sci. 2009 Aug;100(8):1359-65. doi: 10.1111/j.1349-7006.2009.01192.x. Epub 2009 May 19.
7
Immunotoxin: A new tool for cancer therapy.
Tumour Biol. 2017 Feb;39(2):1010428317692226. doi: 10.1177/1010428317692226.
8
Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
N Biotechnol. 2013 Jan 25;30(2):205-9. doi: 10.1016/j.nbt.2012.09.002. Epub 2012 Sep 29.
9
Immunotoxins: the role of the toxin.
Toxins (Basel). 2013 Aug 21;5(8):1486-502. doi: 10.3390/toxins5081486.
10
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Hepatology. 2020 May;71(5):1696-1711. doi: 10.1002/hep.30949. Epub 2020 Jan 27.
引用本文的文献
1
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy.
AAPS J. 2025 May 9;27(4):91. doi: 10.1208/s12248-025-01076-z.
2
The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.
J Exp Clin Cancer Res. 2024 Jun 20;43(1):173. doi: 10.1186/s13046-024-03099-4.
3
Can antibodies be "vegan"? A guide through the maze of today's antibody generation methods.
MAbs. 2024 Jan-Dec;16(1):2343499. doi: 10.1080/19420862.2024.2343499. Epub 2024 Apr 18.
4
In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.
Mol Biol Rep. 2024 Jan 18;51(1):130. doi: 10.1007/s11033-023-09036-6.
5
Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Exotoxin Catalytic Domain for Cancer Therapeutics.
Mol Cells. 2023 Dec 31;46(12):764-777. doi: 10.14348/molcells.2023.0155. Epub 2023 Dec 1.
6
Bringing enzymes to the proximity party.
RSC Chem Biol. 2023 Sep 29;4(12):986-1002. doi: 10.1039/d3cb00084b. eCollection 2023 Nov 29.
7
Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.
Exp Mol Med. 2023 Sep;55(9):1996-2004. doi: 10.1038/s12276-023-01080-3. Epub 2023 Sep 1.
8
Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.
Biomolecules. 2023 Jun 26;13(7):1042. doi: 10.3390/biom13071042.
9
Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25.
Microb Cell Fact. 2023 May 17;22(1):100. doi: 10.1186/s12934-023-02115-0.
10
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
Pharmaceutics. 2023 Feb 22;15(3):727. doi: 10.3390/pharmaceutics15030727.
本文引用的文献
1
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
2
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Mol Cancer Ther. 2014 Nov;13(11):2653-61. doi: 10.1158/1535-7163.MCT-14-0132. Epub 2014 Sep 19.
3
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2.
4
In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.
Mol Cancer Ther. 2014 Aug;13(8):2040-9. doi: 10.1158/1535-7163.MCT-14-0089-T. Epub 2014 Jun 13.
5
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 2013 Oct 23;5(208):208ra147. doi: 10.1126/scitranslmed.3006941.
6
Ribosome-inactivating proteins: potent poisons and molecular tools.
Virulence. 2013 Nov 15;4(8):774-84. doi: 10.4161/viru.26399. Epub 2013 Sep 17.
7
Immunotoxins: the role of the toxin.
Toxins (Basel). 2013 Aug 21;5(8):1486-502. doi: 10.3390/toxins5081486.
8
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
Clin Cancer Res. 2013 Sep 1;19(17):4717-27. doi: 10.1158/1078-0432.CCR-12-3891. Epub 2013 Jul 15.
9
Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.
10
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.
Zotero 插件